Swing Therapeutics

Swing Therapeutics develops digital treatments and services in disease areas where patients are not well-served and where digital interventions may be effective. Its focus is on tackling autoimmune conditions and chronic overlapping pain conditions (COPCs) such as fibromyalgia, where central pain sensitization is a significant factor. The company is investing in research to support the development of prescription-based digital therapies and services. Its near-term goal is to validate its digital therapy and bring it to market as an FDA-cleared prescription digital therapeutic. Swing Therapeutics was founded in 2019 and is based in San Francisco, California.